Congratulations to Dr. Betty Leibold who was awarded a competitive RO1 research grant from the National Institutes of Health, NIDDK Institute. Dr. Leibold's research grant builds on her discovery that the processing of proinsulin is impaired in mice lacking the iron regulatory protein 2 (IRP2). The irp2 -/- mice exhibit elevated proinsulin levels and reduced pancreatic insulin secretion. She seeks to elucidate the mechanism by which IRP2 contributes to proinsulin processing.... Read MoreInternal Medicine
Division of Hematology & Hematologic Malignancies
The scientific focus of our division is the study of blood and bone marrow in health and disease. Our physicians treat patients with blood cancer, such as leukemias and lymphomas; clotting disorders, such as hemophilia; and diseases of iron metabolism, such as hemochromatosis. Starting with Maxwell Wintrobe, one of the founding fathers of Hematology and the University of Utah Medical School, our division can look back at a long-standing tradition of excellence in research, clinical care and teaching.
Last year researchers from our division garnered more than $7,000,000 in grant income, presented their data at major conferences, and published their results in prime international journals. This would not be possible without the University of Utah’s outstanding collaborative environment and its strong scientific foundation.
The annual Hematology Huntsman Disease-Oriented Team 5K Walk is scheduled for Saturday October 15, 2016. The walk/run will start at the Fort Douglas bandstand. Faculty, family, patients and friends are welcome.... Read MoreInternal Medicine
Congratulations to Dr. Deborah Stephens on her recently accepted manuscript in the Journal of Clinical Oncology. The study entitled, " Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736" reported on a two decade follow up by the SWOG Lymphoma Working Group on risk assessment of 400 patients with diffuse large B-cell lymphoma. The group reported that relapse occurred independent of the treatment modality. This highlights the importance of long-term followup studies to assess treatment efficacy.... Read MoreInternal Medicine